Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Why would someone use multiple usernames to post nonsense?
The last time SNY did something like this it blew up. Im not sure about you guys but awe*some*stocks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Things seem to be getting overextended for SNY. Not sure how AWE.some.STOCKS finds all these incredible trade ideas but im happy.
SNY cranking up new highs!
SNY has up 20% in last two months, not bad. But need more clear path for growth of revenue.
SNY needs a clear strategy for its oncology drugs franchise to grow exponentially by acquiring fresh pipelines
SNY should be up today. FDA approved. What is happening? Any idea?
Any thoughts on why so many executives have left? Forced out or leaving on their own?
serious unbiased question? why the strong gain last few months ( even adj for annual dividend)? new trial drug? takeover target? acquisition? Something driving
There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold
Flu vaccines need to be administered annually. Sanofi's research team thinks they can...
Charles A. Henriques ( Global Popularity, A Bright Star In Pharma) Linkedin.com NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
San Francisco Bay Area: Linkedin 1799 Linkedin.com Connections
Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
Received an alert this am about $GCVRZ from http://thesubwaytrader.com/?s=GCVRZ, you may want to take a look. Making money investing. John's collateral corollary: in order to get a loan you must first prove you don't need it.
The Subway Trader: Trading Stocks and Making Money
Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
Just saw this : Sanofi First Quarter Profit Rises Driven by Performance in Specialty HealthCare Division, Consumer Products
BY Midnight Trader — 11:26 AM ET 04/28/2017 Business net income totaled 1.80 billion euros ($1.97 billion), or 1.42 euros per share, compared with 1.72 billion euros, or 1.34 euros per share, in the same quarter a year earlier, results published by company on Friday showed. Net sales increased 11.1% to 8.65 billion euros, lifted by the acquisition of Boehringer Ingelheim's consumer healthcare business and full consolidation of Sanofi's European vaccine unit. At constant business structure and currencies, sales rose 3.5%, the company said.
Genzyme sales increased 15.5% at constant currencies driven by multiple sclerosis products, while sales were down 7.7% at constant currencies at the diabetes and cardiovascular business, dragged down by lower demand for the company's diabetes products in the US, including Lantus for type-2 diabetes.
Sales at the vaccines unit jumped 13.2% at constant structure and currencies led by children's products and at the consumer health care business they were 4.7% higher on the same basis. Stock goes up a whole 13 cents!!!!!!!!!!!!!!!
Mymetics Corp. is an international biotechnology company successfully focused on developing virosome based vaccines to combat human infectious diseases.
http://yugestocks.com/?s=GCVRZ has an alert for $GCVRZ. Did anyone happen to see it as well? Looking for some good positive information from the company! Sattinger's law: it works better if you plug it in. Investing day trading.
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
SNY should buy Fitbit.
unbelievable 37000 a year for an eczema drug. sorry people preying on people who suffer from this doesn't make me want to be want to be an investor.